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ABSTRACT 
Social science research on lifestyle related diseases typically focuses on patient 
understandings and beliefs and takes the clinical risk for granted. We interviewed thirty 
healthy UK patients at high risk of heart disease, recruited from a family history trial, two 
weeks and six months after a discussion with a clinician about their risk, lifestyle and 
medications. The participants took four different paths: (i) pharmaceutical (most 
common, risk reduction with cholesterol lowering statins), (ii) mixed (statins and 
behaviour change), (iii) behavioural (behaviour change, focus on well-being) and (iv) 
“lost” (no prevention, difficult social/personal circumstances). Drawing on Berg we argue 
that CHD risk assessment technologies are formal tools that do not represent but generate 
high risk in a way that patients often experience lifestyle change as futile, because it 
rarely reduces their cholesterol to targets defined by the tools. We suggest social 
scientists studying incipient or “protodiseases,” such as CHD risk, should not only focus 
on understandings but also investigate the technologies (and the associated guidelines, 
policies, clinical practice and pharmaceutical industry operations) that generate them and 
patient experiences of them. However technologies do not determine experience, and we 
also discuss elements that direct patients down other than the pharmaceutical path. 
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INTRODUCTION 
Screening for and preventing lifestyle-related diseases is high on Western 
governments’ agenda. The UK Department of Health (2008) has recommended screening 
all 40-75 year-olds for cardiovascular risk. Yet, there are no qualitative studies on how 
individuals who are healthy but at risk of heart disease actually experience screening and 
primary prevention.  
 
Lay Understandings of Lifestyle Related Diseases 
Health psychologists, using, for example, the self-regulatory model (Leventhal, 
Nerenz & Steele,1984), study lifestyle-related disease focusing on cognitive processes, 
such as perceived causality or sense of control, suggested to mediate individuals’ 
responses to interventions. Sociologically oriented qualitative studies often reflect similar 
ideas, discussing how causal understandings (e.g. Schoenberg, Amey & Coward, 1998) 
or “lay epidemiologies” (e.g. Davison, Davey-Smith & Frankel, 1991) guide or might 
guide individuals’ preventive actions. 
A systematic review of quantitative studies on causal beliefs about heart disease 
concluded that individuals most often attributed heart disease to lifestyle and chronic 
stress (French et al 2001). The belief that lifestyle causes heart attacks/diabetes has been 
observed to be associated with positive behavioural change in quantitative (Weinman et 
al 2000) and qualitative studies (Schoenberg, Amery & Coward, 1998), although later 
research has suggested that this relationship is more complicated (French et al 2005). 
Beliefs that disease is down to luck or genes have been considered problematic, as 
fatalism is feared to render individuals less motivated to change behaviour. Qualitative 
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research has suggested that individuals who understood their diabetes as inherited were 
less likely to have changed lifestyle (Hunt et al 1998, Schoenberg, Amey & Coward, 
1998). It has, however, also been suggested that family history could motivate healthy 
lifestyle (Hunt et al 2000).   
Few studies have examined how individuals’ understandings develop after an 
intervention. Wiles (1998) observed that information delivered to patients after a heart 
attack about a quick recovery could either lead them to consider themselves “recovered” 
or hopeless. Both scenarios led the participants to abandon lifestyle advice. Lawton et al 
(2008) noted that participants’ accounts of what had caused their diabetes shifted based 
on their experiences of treatment and disease progression i.e. if dietary changes were not 
effective in controlling glucose levels, they tended to attribute disease to genes. Marteau 
et al (2004) found that individuals, who had undergone genetic, as opposed to clinical, 
assessment of familial hypercholesterolaemia were more likely to believe in the 
effectiveness of cholesterol lowering statins.   
 
From understandings to technologies 
In the course of our research we observed that causal understandings did not 
necessarily or primarily guide our participants’ preventive strategies. Rather, we noticed 
that our participants’ experiences were often dominated by risk assessment technologies 
and cholesterol lowering statins. To make sense of our observation we drew on Marc 
Berg’s (1997) discussion of how “formal tools” generate the clinical states they seek to 
represent. CHD risk assessment technologies are formal tools in that they aim to 
represent or model risk of heart disease. Nevertheless,they do not reflect any 
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encompassing risk but focus on very specific inputs, such as cholesterol and blood 
pressure levels, age, gender and smoking status. Based on these inputs the computational 
tools estimate whether an individual is at “high risk,” defined as having over 20% chance 
of developing CHD in the next 10 years (British Cardiac Society et al 2005). Those at 
high risk are recommended for treatment with statins by the UK government National 
Institute for Health and Clinical Excellence (NICE, 2006).   
To make sense of how formal tools generate clinical phenomena Berg (1997) 
suggests studying their history. The history of CHD risk assessment is bound up with the 
development of pharmaceuticals. Greene (2007) has chronicled how cholesterol was 
associated with CHD already in the first Framingham studies in the 1950s, but as the 
early lipid lowering drugs proved dangerous or unpalatable and lifestyle interventions 
ineffective clinicians had lost interest in cholesterol by the 1970s. The transformation of 
one’s cholesterol level into a popular icon for heart disease in the 1980s and 1990s was 
intimately associated with the development of the statin, an effective medication with 
fewer side effects and propagated by health campaigns, such as the US “Know Your 
Number” campaign (Greene, 2007: 173). Thus, rather than risk factor being identified 
first and treatment second, cholesterol only gained traction as a risk factor after the 
development of targeted drugs. This co-development of a risk factor and drugs has 
continued in the last decade, as the category of high cholesterol has expanded to 
encompass increasingly lower levels of cholesterol following trials, many of which have 
been funded by the pharmaceutical industry (Greene, 2007). 
The CHD prevention in the USA has been very focused on cholesterol as 
indicated by the title of the main prevention guideliens, ‘National Cholesterol education 
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Programme’ (NCEP), even if the programme recommends using the Framingham 
equation—which includes other risk factors, such as smoking, blood pressure and family 
history—when establishing risk and the need for treatment (NCEP 2001). The UK 
prevention policy has been more clearly founded on the use of multifactorial risk 
assessment tools. Will (2005), however, has documented the fact that the early CHD risk 
assessment tools in the 1990s were promoted mainly to determine prescribing thresholds 
in order to facilitate the rationing of statins in the public healthcare system. Similar to the 
US, the UK thresholds for high risk, cholesterol and prescribing have been pushed down 
following clinical trials (e.g. NICE, 2006).  
The historical research indicates that CHD risk assessment technologies are 
designed as prescribing aids and embody a consensus between epidemiological research, 
public agencies focused on cost-effectiveness, such as the US NCEP and the UK, and 
pharmaceutical companies on how to define individuals at risk of heart disease, targeted 
for  drug treatment.  As discussed in the previous section, social science research on 
lifestyle related diseases tends to focus on patients’ understandings and beliefs (residing 
in their cognition) that are viewed as separate from the taken-for-granted clinical risk. 
However, the estimate of CHD risk is not a natural fact but focuses attention on very 
specific aspects of reality, such as cholesterol, and articulates socially negotiated 
thresholds for high risk, cholesterol and prescribing. Against this we ask: How does the 
way in which contemporary assessment technologies generate CHD risk shape patients’ 
experience?  
To begin to answer this question Woolgar's (1991) notion of how technologies 
configure users by shaping their identities and constraining their actions is useful. 
 7
Individuals defined as at high risk by the CHD tools end up with what Rosenberg (2007: 
66) calls “protodisease.” Rosenberg (2007: 69) argues that these new incipient ills (high 
cholesterol or glucose) are detected by modern laboratory techniques but hark back to 
pre-germ theory moral conception of illness, where bad habits slide gradually into 
disease, a sanction for breaking behavioural norms. The reform of habits is also 
recommended for those at high CHD risk; the clinical guidelines accompanying 
assessment tools recommend lifestyle intervention to encourage patients to “make 
healthier food choices” (British Cardiac Society et al 2005: 2). However, the guidelines 
also set very specific biochemical targets for patients at high risk, including total 
cholesterol of less than 4.0 mmol/l or its reduction by 25% with lipid lowering drugs 
(British Cardiac Society et al 2005: 2). Clinicians, studied for an associated project, noted 
that such targets are difficult to achieve with lifestyle changes; they estimated that 
patients’ cholesterol decreased “10%” at best with behaviour change, whereas statins 
typically lowered cholesterol by “30%.”1 The way in which CHD risk assessment 
technologies and associated clinical guidelines configure patients at high risk, thus 
creates a contradiction between the moral, public health agenda endorsing benefits of 
behaviour change and the precise biochemical targets, which frequently can only be 
achieved with drugs. 
There are no studies on how real users, who have undergone CHD risk assessment 
and prevention, experience this contradiction. A focus-group study found that patients 
were frustrated with the restriction of heart disease prevention to the clinical monitoring 
of cholesterol levels and manipulating them with medications (Crinson et al 2007). Risk 
                                                 
1 Focus-groups with clinicians (n=32) in 6 GP surgeries participating in the trial, conducted in 2007-2008. 
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assessment technologies may play a greater role in influencing individuals’ experience of 
CHD risk, because it is considered imperceptible (Angus et al 2005). As such, CHD risk 
is a prime example of contemporary risks discussed by Beck (1992), which require 
scientific knowledge and instruments to become constituted as hazards at all, as they 
cannot be assessed by everyday means such as felt pain and discomfort.  
Still, risk assessment technologies, any more than any technology (see 
Oudshoorn, 2005), do not determine experiences. Whilst clinicians and some patients 
may consider conditions, such as blood pressure, detectable with specialist technologies 
only, individuals may have other means for assessing them. For example, patients 
frequently resort to physical and psychological states, such as headaches or feeling tense, 
to assess blood pressure (e.g. Leventhal, Nerenz & Steele, 1984; Morgan & Watkins, 
1988; Benson & Britten, 2002). In what follows we will examine how clinical and lay 
ways of configuring CHD risk interweave and occasionally collide with each other, 
illuminating the kinds of preventive paths they forge.	
      
METHODS 
Our qualitative study was nested within a trial examining the clinical utility of 
family history in cardiovascular risk assessment (for the protocol see Authors, 2009). The 
trial was conducted in 24 general practices in diverse socioeconomic areas in the UK East 
Midlands and South West. A total of 625 30-65 year-old patients completed the study; 
the inclusion criterion was being offered a cholesterol test and cardiovascular risk 
assessment as part of normal care. Individuals who had developed heart disease or 
diabetes or had been prescribed statins prior to the study were excluded. In the 
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intervention arm the participants’ family history of CHD was formally assessed using a 
self-completed questionnaire. Participants at high risk (British Cardiac Society et al 2005) 
were invited to a consultation with their clinician to discuss their risk and 
lifestyle/medications. We recruited “high risk” participants for a qualitative interview 
approximately two weeks and six months after the consultation. We used maximum 
variation sampling (Patton, 2002) in terms of gender, socioeconomic and family history 
status. We recruited both from intervention and control arms, seeking to ascertain 
possible qualitative differences. Recruitment was stopped when saturation was reached 
for the main topic of this article, that is, the role of risk assessment technologies in 
shaping patient experiences in the 6 months after the intervention, even if with slightly 
different outcomes.  
The qualitative interviews were conducted by experienced researchers (AB and 
BA) using the “discovery interview” (NHS Modernization Agency, 2001) format. We 
asked the participants to tell their experience chronologically, such as how they ended up 
having the cholesterol test, what they thought of being classed at high risk, what 
interactions they had had with clinicians and what, if anything, they had done with the 
information. In the second interview, six months later, the participants were asked how 
they had been getting on, what they thought of the risk assessment and their risk now and 
if they had had further contact with clinicians; each was also asked personalised follow-
up questions based on a review of the first interview. 
The interviews were recorded and transcribed. The transcripts were analysed 
using constant comparative thematic analysis, a selection of transcripts being inter-rater 
checked by both social science and clinical members of the team (Glaser, 1965). Our 
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analysis was informed by the sociological tradition of discerning individuals’ “careers” or 
paths when they progress through experience (e.g. Becker, 1963), which suited following 
patients in the aftermath of primary prevention intervention. 
 
RESULTS 
Recruitment and main themes 
After receiving ethical approval we invited a total of 49 participants, mainly by 
phone, to the initial interview, of whom 38 (78%) agreed to an interview (for details see 
Authors, 2010). Of the 38 initial participants, 30 were followed up at six months; one 
refused to give a follow-up interview, two could not be located and the last five were not 
contacted due to the impending maternity leave of the interviewer. The characteristics of 
the participants in terms of gender, age, socioeconomic and family history status and 
whether or not they were prescribed statins initially and at follow-up are shown in Table 
1. All except for two participants were white. 
 
[Table 1 here] 
 
The interviews took place in 2007-2008. Most of the interviews were face-to-face 
and took place in the participants’ home; ten of the initial and eight of the follow-up 
interviews were conducted by phone, when most convenient for the participant. We did 
not observe substantial differences between face-to-face and phone interviews. 
Some of the participants were taking antihypertensives and were recruited to the 
study when having a blood-pressure check, others were recruited, for example, during 
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health-checks or when consulting for unrelated illnesses. Thus, some of our participants, 
particularly the hypertensives, had been consulting their doctors over heart disease risk 
for some time, whereas for others the study was the first time they had been alerted to 
CHD risk. 
In the initial interviews participants were often “shocked” about being identified 
at high risk, as they perceived themselves having a “healthy” lifestyle. They sought to 
normalise their risk and often planned some preventive actions (Authors, 2010). At 
follow-up our participants’ experiences differed more substantially, and we identified 
four preventive paths: (i) pharmaceutical (most common, focused on decreasing risk with 
statins), (ii) mixed (engaged with prevention with statins and behaviour change), (iii) 
behavioural (focused on behaviour change) and (iv) “lost” (not engaged with prevention). 
The paths were shaped by an interaction between several elements, but each path was 
dominated by different elements. In Table 2 we summarise the main characteristics of the 
four paths in terms of (a) dominant elements, (b) how patients understood the causes of 
their risk, (c) participants’ personal and social circumstances and (d) the outcome of 
prevention as described by patients at follow-up. 
     
[Table 2 to be inserted here] 
 
To give a sense of the proportion of the different paths taken, thirteen, or nearly 
half, of our participants had followed the pharmaceutical path, the mixed path was 
followed by five participants, and the behavioural path by another five participants. 
Seven participants’ experiences were categorised as “lost.”  In what follows we will 
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discuss the four paths through illustrative individual cases, which allow us to present the 
contextual and evolving nature of the experience.   
 
Pharmaceutical path 
The case of Howard (all names are pseudonyms) illustrates how risk assessment 
technologies, risk and cholesterol levels and managing them with statins ended up 
dominating the experience. 
 
Howard 
Howard was a part-time driver and handyman in his early sixties, who lived with his 
wife, Anne, also in the study and also classed at high risk of CHD.  In the initial 
interview he told how he had been informed that his risk of heart disease was “30% or 
40%.”  He sought to normalise this risk, commenting that this information could be given 
“to practically everybody in the country at my age.” He doubted health advice, saying he 
agreed with the idea that being “overweight” would make you at risk but “disagreed” 
with the idea that “eating the wrong foods” would have anything to do with it, continuing 
that “we’ve got one book that says you can eat eggs and another book that says you can’t 
eat eggs.” He also added that in the “lists” “they” gave him on foods to eat “there was 
nothing there that you can grasp hold of,” and that together with his wife they had 
concluded that they had a “reasonable” lifestyle, “not overdoing it, but not under-doing 
it.” 
Howard’s doctor had initially suggested he try lowering his cholesterol with diet. 
But after a month he had gone to the practice nurse, who had told him: “You can eat the 
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best diet and best weight and God knows what, but you won’t bring your cholesterol 
down. You’ve got to have tablets.” At follow up Howard told that statins had brought his 
cholesterol down from seven to three. He said that together with his wife they had 
initially tried “dieting” but “that’s gone by the board now,” and he was “experimenting” 
to see if the medications alone kept the cholesterol down: 
 
H It’s a bit of an experiment on my side, really, ‘cause, um, [the cholesterol] 
went down to three. So now I’ve gone back to what I was doing before. 
Then when I have it taken again, if it’s gone up I know it’s me lifestyle, so 
I’ll alter me lifestyle. It’s no use altering your lifestyle and starving 
yourself of something you like if you don’t need to. 
I Yeah, if the cholesterol is three? 
H  If the cholesterol stays the same, then I know … the tablets are keeping it 
in check.  
 
Howard was in the intervention arm but did not have a clinically significant 
family history; both initially and at follow-up he considered he was “inclined” to have 
high cholesterol, elaborating that the inclination was “in your genes and in your 
lifestyle.” The clinician had told him that his risk for CHD was down to his age, blood 
pressure and cholesterol (the main components of CHD risk assessment). Howard had 
been taking antihypertensive medications already before and was prescribed statins as 
part of the study and concluded the problem had been solved: “I’m dealing with the high 
blood pressure with the tablets, so me blood pressure isn’t high. And then they put me on 
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statins … and the cholesterol’s come right down now. I’m down to three. So, there’s no 
problem, you know.” 
Howard attributed his risk of CHD to inheritance and his lifestyle. However, he 
considered his and Anne’s lifestyle “reasonable,” which he defined in opposition to 
excess, such as being overweight or overly rigid and “overdoing it” (see Crawford, 1984). 
He acknowledged that living more healthily could reduce his risk, and he had briefly tried 
small changes. Yet, he, directly and indirectly, communicated that the lifestyle advice he 
was provided was beyond what he considered “reasonable,” referring to it in terms of 
“starving,” evoking contradictions in health advice with regards to eggs (also e.g. 
Gabhainn et al 1999) and lack of access to healthy foods (also e.g. Clark et al 2010). In 
this situation, he had solved the problem of high risk and cholesterol by taking statins. 
Howard’s experience is not primarily mediated by causal understandings. Rather his 
experience is shaped by the risk assessment technology, which constructed the problem 
for him in the first place in terms of CHD risk percentages and cholesterol levels. The 
risk, configured in terms of these abstract figures, could be effectively decreased with 
pharmaceuticals, which Howard considered solved the problem. Other elements, such as 
Howard’s reluctance towards lifestyle advice, and his wife’s and clinician’s views, 
further supported his preventive strategy focused on medications without the need to 
disrupt his “reasonable” lifestyle. 
 
Steve 
In a couple of cases participants had gone down the pharmaceutical path having 
tried behaviour change first. To illustrate this we will discuss the case of Steve. 
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Steve was in his early fifties, worked as a school mealtime assistant and lived on a 
council estate with his wife and teenage daughter. Steve was in the intervention arm and 
was identified with a positive family history.2 However, in the initial interview he 
concluded that health was “90%” down to “the life you lead, I mean, if you go out 
boozing and womanising … you’re going to have a short life.”  The nurse practitioner 
had given him “a long list” of things not to eat, and he had changed, for example, from 
eating beef and pork sausages to eating turkey ones. At follow-up he reported he had 
changed his diet and even drank soya milk, but both his bad and good cholesterol had 
gone down, he had had another birthday, which also increased his risk estimate, and his 
risk had been calculated as higher than initially. At this point his wife joined the 
conversation and summed up their experience: 
 
Wife: Mind you, you were quite astonished, you had the test done and then [the 
nurse] said eat or try to eat this and that and we bought all the stuff and that 
and yet it went up, didn’t it? 
S Or that it…it was the bad one that went down…no, the good one that went 
down… 
Wife: It reversed itself, wasn’t it? 
S Yeah, the bad one went down, but so did the good. 
Wife: Like I said, you know, sometimes, eating the good stuff don’t help you. … 
Cause it was expensive, the stuff I was buying as well. 
                                                 
2 A positive family history was defined as having a first degree relative, who had developed heart disease 
before the age of 65. 
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At follow-up the clinician had prescribed him statins, telling him “there’s nothing 
else you can do,” and Steve concluded that his cholesterol was “hereditary anyway.”  
Steve’s experience illustrates a discrepancy between the public health and clinical 
discourse, which emphasises the importance of lifestyle change for those at high risk, and 
CHD risk assessment and accompanying guidelines. The contradiction is created in 
particular by the specific target levels for cholesterol that are set by the guidelines and are 
difficult to achieve with lifestyle change. So, Steve was encouraged to change his 
behaviour, but this did not decrease his absolute risk and the balance between his high-
density lipoprotein or good cholesterol and total cholesterol. He concluded that his 
cholesterol did not behave in the way indirectly promised by the clinician, who gave him 
lifestyle advice (as the reasonable expectation is that, if one is given advice, following it 
should decrease the cholesterol identified as the problem), therefore it must have been 
inherited and needed to be controlled with drugs.  
 Other researchers have made similar observations. Lawton et al (2008) suggested 
that patients, whose glucose levels could not be controlled by lifestyle, reinterpreted their 
propensity to diabetes 2 as genetic. Marteau et al (2004) concluded that genetics based 
assessment increased trust in the effectiveness of medications. More broadly, Rose 
(2007) has argued that health conditions, from depression to cardiovascular disease, are 
no longer considered to be caused by life events or lifestyle but by genetically determined 
anomalous biochemistry to be corrected by pharmaceuticals that target the anomaly. 
However, none of these studies have explored how risk assessment technologies fuel 
the reliance on pharmaceuticals and sometimes on genetic explanations. These 
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technologies are designed to identify patients at high risk for pharmaceutical treatment 
(Greene, 2007; Will, 2005). This creates a dilemma for both clinicians and patients, who 
seek to adhere to the traditional, often moralistic public health dictum to change 
behaviour, which rarely helps the patients to decrease their cholesterol to target levels. 
Clinicians and patients may, subsequently, resort to genetic explanations to explain the 
seeming recalcitrance of cholesterol. Thus, the abandonment of lifestyle advice is not 
necessarily or primarily driven by causal understandings. Rather, genetic understandings 
become a post hoc rationalisation to make sense of a situation where cholesterol has 
defied expectations and has not decreased to recommended levels despite the patients’ 
efforts to change their habits. Yet, Steve’s preventive strategies are not determined by 
technologies and clinical recommendations only. Similar to Howard’s case, Steve’s focus 
on pharmaceuticals is also supported by his wife and their joint experience of lifestyle 
change as cumbersome and costly. 
 
Mixed path 
The mixed path, characterised by prevention with both medications and lifestyle 
changes and frequently sustained by a supportive family and clinicians, is illustrated by 
the experience of Jean. 
 
Jean 
Jean was a homemaker in her early sixties, whose husband drove a taxi. She was in 
the control arm but volunteered in the initial interview that her father had died of heart 
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disease in his late fifties, which had made her aware of risk of heart disease. In the initial 
interview Jean related that after the risk assessment she had been prescribed 
antihypertensives and started “thinking” more about her cooking, although considered 
that she ate “fairly sensibly.” She had already altered her cooking practices before in 
order to support her husband, who had suffered a mini-stroke a couple of years earlier, in 
lifestyle change. At follow-up Jean had been prescribed statins, because her cholesterol 
had not decreased sufficiently, and her clinician had suggested to her that her cholesterol 
“might not be what you eat, it might just be hereditary.” She had, however, maintained 
healthier eating and cooking habits and continued to “have more fruit, trying to keep off 
pastry stuff, grilling, as much as I can, not using the frying pan.” Jean also continued to 
support her husband in a healthier lifestyle, for example, by putting “a little bowl of fruit 
out” to entice him. On his behalf, her husband had bought her an exercise bike for 
Christmas, which she used twice a day when watching television; the bike stood next to 
the television in the lounge during the interview. 
At follow-up Jean concluded that “the tablets I’m on have lowered the blood 
pressure and are lowering the cholesterol.” Later in the interview Jean contemplated on 
the effects of her lifestyle changes: “while I’m watching me diet I’m hopefully getting 
less at risk.” Yet, she struggled to assess the effect of her behaviour changes on her 
cholesterol:   
 
J Well, I don’t know, [the cholesterol going down] could be a combination of the 
tablets and watching me diet more, really. 
I But before you went on the statins? 
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J Before I went on the statins …well, I don’t think [the cholesterol went down], 
that’s why we went on them.  
I Because it didn’t have much of an effect? 
J No, it didn’t, not at that time, anyway, whether in the long term it might have 
done, I don’t know. 
 
Jean’s understandings of the cause of her risk, her clinician’s casual comments about 
her cholesterol being hereditary, her understanding of her previous lifestyle as “sensible” 
and her spouse also being at risk were rather similar to Howard’s and Steve’s situations. 
Despite these similarities, patients taking the mixed path, such as Jean, maintained 
their behaviour change. The distinctive feature of these participants’ experience was that 
they were supported by, or supported, other family members in behaviour change, which 
in Jean’s case took a distinctly gendered form of taking responsibility for her husband’s 
lifestyle (Radley & Green, 1996, on family support in general Knutsen & Knutsen, 1991). 
Jean and others classed in the mixed path did not necessarily experience lifestyle change 
as pleasurable; but they did not experience it as negative the way participants taking the 
pharmaceutical path did, and at follow-up they had integrated the changes into their 
everyday routines. 
However, the risk assessment technologies also shaped the experience of those on 
the mixed path. The CHD risk assessment initially identified Jean at risk and identified 
elevated cholesterol as one of the key factors. Subsequently, the risk assessment 
guidelines indicated that that her lifestyle changes had not reduced her cholesterol to 
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target levels and that she needed medications. At follow-up she was aware that 
medications had reduced her blood pressure and cholesterol. However, Jean struggled to 
assess the effects of her lifestyle changes, hoping they were lowering her risk. Similar to 
Steve’s case, Jean’s experience highlights the contradiction between public health 
messages on benefits of lifestyle change and the logic of the risk assessment framework, 
which cast doubt on the effectiveness of behaviour change. 
 
The behavioural path 
The behavioural path, characterised by behaviour change and the use of embodied 
sensations to assess risk, is illustrated by the experience of Richard. 
 
Richard 
Richard was an engineer in his late fifties and lived with his wife; his adult 
daughter lived close by with her family. He was in the control arm and did not discuss 
heart disease in relation to family history in the initial interview. He had been identified 
with high cholesterol years ago and had changed his lifestyle, shifted to “granary bread” 
and still “[ate] loads of fruit and veg [and] exercise[d].” He also told that he played golf, 
bowled and danced with his wife. However, when he changed his behaviour his 
cholesterol did not go down. After the risk assessment within the study his doctor had 
suggested he take medications to reduce his cholesterol, but Richard said he was not “one 
to pop pills” and said he would rather do it “naturally.” At follow-up Richard had done 
more exercise and joined a gym where he went together with his adult daughter, noting 
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they “boosted” each other. He had lost nearly a stone in weight. He had not further 
discussed CHD with his doctor. When asked if he felt different about his risk of heart 
disease, he replied: I don’t feel so bad, you know, I feel better for going to the gym, if 
you like. … I feel better for it, so maybe little less [at risk] perhaps. 
Richard did not discuss possible causes of his risk much, but at follow-up he 
stated that, based on his experiences, he had “no control over” his cholesterol and 
continued to reflect on his sister who had “high cholesterol, as well. So, whether that’s 
anything to do with it or not, I don’t know.” Richard’s experience illustrated an 
interesting case where he had been committed to lifestyle change long-term, yet had not 
seen it produce effects in terms of decreased cholesterol, leading him to conclude that he 
could not control it and entertaining the possibility his high cholesterol was hereditary. 
Such frustrating experiences and understandings could have led Richard to abandon 
behaviour change. But, supported by his family and having had a long history of trying to 
lead a healthy lifestyle as well as being reluctant to take medications on the grounds they 
were “unnatural” (also e.g. Benson & Britten, 2002), Richard sustained behaviour 
change. 
Richard’s experience is partly shaped by CHD risk assessment technologies, 
which identified him at risk and, in the past, had indicated that his behaviour change had 
not decreased his cholesterol. Rather than stay fixated on the clinical measure, Richard 
had resorted to embodied sensations as an alternative means for appraising the effects of 
his actions. Interestingly, all participants, who had changed their behaviour but were not 
taking statins at follow-up for varied reasons (doubts about medicines, side-effects or not 
being offered medications by their clinicians), commented on enhanced physical well-
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being and associated this with being less at risk. The comments varied from mentions of 
enhanced general well being (“feeling much better”) to enhanced ability to perform 
everyday actions (walk up hills “without huffing and puffing”); several, including 
Richard, mentioned weight loss. 
 Embodied sensations have been considered a problematic way of assessing 
imperceptible conditions, such as blood pressure (Morgan & Watkins, 1988), because 
they can mislead individuals about need for treatment. Richard’s case illustrates that 
embodied sensations can be an important motivational factor for lifestyle change. 
Further, we argue that Richard “configures” heart disease risk differently from clinical 
assessment. Rather than evaluate his risk based on specific clinical measures (cholesterol 
etc), he assesses his risk in terms of broader embodied sense of health or quality of life 
(“well being”). Even if Richard seems a model patient in terms of the public health 
recommendation of behaviour change, in terms of CHD risk assessment his actions 
seemed not to produce “real” results (on technologies and “real” representations see 
Latour, 1998). Similar to Steve’s and Jean’s cases, Richard’s experience highlights the 
contradiction between lifestyle advice and CHD risk assessment for patients at high risk, 
although each had a different outcome.    
 
The lost path 
Participants classed as taken the lost path were not engaged with either 
medications or lifestyle change and their experience was frequently marked by 
overwhelming personal and/or social circumstances. To illustrate the lost path we will 
discuss the experience of Gill; she is an “intense” case (see Patton, 2002: 243) in that her 
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circumstances were more difficult than of most others, but they highlight the way in 
which these participants often experienced multiple health, social and personal 
difficulties simultaneously. 
 
Gill 
Gill was in her fifties and at the time of interview she was out of work. She was 
caring for her disabled husband as well as her elderly father-in-law; the family had 
recently lost their housing and were living in makeshift accommodation in the 
countryside. Both Gill and her husband had experienced multiple health problems. She 
had originally contacted the doctor because of “tightness” in the chest, her cholesterol 
was identified as high, but not as high as it had been some time before, after which she 
had lost weight. Gill was in the control arm but volunteered that there was “no reason to 
believe that it’s anything hereditary, because mum and dad, they died of cancer.” Gill 
said that the doctor had told her they could not prescribe her tablets to lower the 
cholesterol, because she had thyroid problems. 
At follow-up Gill had not changed anything. She spent a good while talking about 
her kidneys that were recently found to be “not working” and her husband’s health issues, 
and said she was dissatisfied with doctors, who kept “pooh poohing” her and making her 
feel like she was “a bit of a waste of space” when, for example, she asked them to take 
her blood pressure. She said she thought “eating wrong foods” made cholesterol high but 
continued she had “no idea at all” what made cholesterol high and wondered if the 
cheese, olives and yogurts she ate increased cholesterol. Most people on the lost path 
concluded at follow up that their risk was the same as before as they were aware they had 
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not done anything different. Gill also did not think her risk had changed during the study 
period but thought she might be less at risk than when she was heavier. Still, she 
considered her “stress levels” put her at risk and continued that “not having any money,” 
“[partner’s] problems” and being “prone to paranoia” stressed her out. She concluded her 
chest pains and stress were linked:           
 
I think it’s all due to me not knowing about my health necessarily and not feeling 
100% and having to look after [partner] and his father, causes me to have these 
chest pains, and I think that’s where these chest pains are coming from. 
 
Gill’s case illustrates how difficult personal and social circumstances had 
overwhelmed her ability to engage with heart disease prevention, even if she was 
concerned or even anxious about her overall health. Gill’s experience was typical for 
those whose experiences we classed as following the lost path in that it was characterised 
by difficult social circumstances, such as financial and housing problems, as well as 
physical and mental health problems, which all made the prospect of heart disease fade 
into the background in relation to the pressing and constantly evolving problems. 
Participants following the lost path, including Gill, also had lower socioeconomic status 
and frequently had poor communication with their clinicians, often being confused or 
unclear about preventive actions or treatments and feeling ignored by professionals. In 
Gill’s case all these elements came together, which also illustrates the fact that difficulties 
tended to cluster in this group. 
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 It has been observed that lower socioeconomic status correlates strongly with 
heart disease (Marmot & Elliot, 2005). Preliminary findings of a Canadian study found 
that deprived men could not engage with CHD prevention (Savage, Dumas & Bergeron, 
2009), and individuals with low SES receive poorer care from their clinicians (Hart, 
1971). Therefore, in Gill’s cases, as well as in most other cases in the lost group, the 
obstacle for multidimensional prevention is not reductionist technologies but deprivation, 
which affects individuals’ lives, physical and mental health and treatment in clinical 
settings and needs to be addressed through broad social programmes addressing health 
and social inequality.              
 
CONCLUSION 
When we initiated our qualitative study, nested within a family history trial, we 
wanted to explore, whether and how a formal family history assessment might shape our 
participants’ experiences. Somewhat to our surprise we did not observe substantial 
differences between the experiences of participants in the intervention and control arms 
or between those who had and those who did not have a clinically significant family 
history of CHD. Those participants who had been assessed to have a positive family 
history usually had a clearer understanding of CHD running in their family than others. 
Still, nearly all our participants understood their risk to be partly inherited, partly due to 
lifestyle, indicating that such understanding has become “common sense,” as observed by 
Davison, Davey-Smith and Frankel (1991). 
Further, understanding heart disease as partly inherited did not necessarily or 
primarily influence our participants’ preventive strategies. Rather, the experiences of our 
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participants were often dominated by CHD risk assessment technologies, cholesterol 
levels and cholesterol reducing statins. Drawing on Berg’s (1987) work on formal tools 
we noted that CHD risk assessment does not “reflect” risk but generates it by focusing 
attention and action on very specific elements, such as cholesterol. The risk assessment 
technologies and guidelines shape patients’ and clinicians’ experiences in three main 
ways. Firstly, they generate measures of risk, such as the chance of developing CHD in 
the next ten years (in percentages). Secondly, the technologies and guidelines create 
expectations, such as target levels for cholesterol. Thirdly, the CHD prevention 
framework provides rewards, such as sense of safety (of not being at risk) for reaching 
target levels. The risk assessment and treatment framework often creates a situation 
where lifestyle change seems unnecessary or futile; thereby disempowering both 
clinicians and patients in their effort to reduce patients’ behaviour as it does not seem to 
translate to real, measurable improvements. 
However, technologies do not determine experiences and not all our participants 
progressed down the “pharmaceuticals only” path. Patients on the mixed and behavioural 
paths had integrated some of the lifestyle advice into their everyday lives, which was 
associated with family support or motivated by embodied sensations of well-being. 
However, risk assessment technologies also shaped these experiences, casting doubt on 
the effectiveness of behaviour change, which did not seem to have “real” effects, as 
measured by cholesterol targets. These findings indicate that if one wants to encourage 
patients at high risk of CHD to change lifestyle, it might not be a good idea to be fixated 
on clinical measures, such as cholesterol. Rather, it might be best to emphasise broader 
benefits of lifestyle change for general health, quality of life and mobility i.e. well-being, 
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which, in the end, might be a more appropriate indicator of overall health than total 
cholesterol. Our study also confirms that family plays a key role in prevention (e.g. 
Knutsen & Knutsen, 1991), and that social deprivation hampers the ability of individuals 
to take care of their health. Deprivation cannot necessarily be ameliorated by clinical 
practice, except that it is often perpetuated by the tendency of clinicials to provide 
deprived individuals poorer care than the norm, according to the well-known inverse-care 
law (Hart, 1971). 
Overall, the trouble with much social science research on lifestyle related diseases 
is that it concentrates on patients’ understanding and takes the clinical risk for granted. 
Thus, research often views the root of any problems, such as neglect of lifestyle advice, 
in patients’ cognitive processes (understandings and beliefs). We acknowledge that risk 
assessment technologies operate partly through understandings by directing attention to 
biochemical targets. Other understandings, such as considering heart disease risk partly 
hereditary or health advice unreasonable, also shaped the experiences of our participants 
on the pharmaceutical path. However, we argue that the focus on understandings 
obliterates the way in which risk assessment technologies and clinical guidelines shape 
individuals’ experiences of lifestyle related diseases and often drive 
pharmaceuticalization. We suggest social scientists studying the increasingly prominent 
incipient or “protodiseases” (Rosenberg, 2007) pay critical attention not only to patients’ 
cognition but also to the way in which these conditions are being created in specific ways 
by the risk assessment framework, which encompasses technologies, public policies, 
clinical guidelines and practice as well as industry operations. 
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Our study is the first to explore the experiences of healthy patients at high risk of 
CHD undergoing primary prevention intervention, which forms a key part of Western 
government’s health policy. Previous studies have all focused on experiences of 
secondary prevention i.e. on individuals who have already developed heart disease and 
where issues, such as being cured or fixed and loss of physical strength become important 
(e.g. Radley & Green, 1986; Wiles, 1998, Ononeze et al 2006). Focusing on those at high 
risk reveals how the category as such, with its orientation towards treatment, shapes the 
experience of those classified in this way, regardless of whether or not they take 
pharmaceuticals alone. However, as fewer participants had maintained their behaviour 
change (in the mixed and behavioural paths) our results in terms of what sustains 
behavioural change are indicative only. For this reason, it might be interesting to explore 
the experiences of those at moderate risk of CHD, who may not be recommended 
medications so readily. 
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TABLE 1 
 
Gender  
Female 10 
Male 20 
Age  
30-49 2 
50-59 11 
60-65 17 
Socioeconomic status  
I-II (managerial & 
professional) 
10 
III-VI (intermediate) 5 
VII-VIII (manual and not 
working) 
15 
Arm of study  
Control 10 
Intervention (family 
history assessment)3 
20 
Statins prescribed  
At 2 weeks4 16 
                                                 
3 Eleven of the twenty had a clinically significant family history. 
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At 6 months 20 
 
Table 1. Characteristics of participants 
                                                                                                                                                 
4 Two of the 16 had stopped taking the medications at follow-up due to side-effects. 
 
 
TABLE 2 
 
 
  Dominant 
elements 
Cause Personal & 
social 
circumstances 
Outcome 
 
 
Pharmaceutical 
path 
Reducing 
cholesterol 
and risk with 
statins 
Hereditary & 
behaviour, 
sometimes 
hereditary 
post hoc  
Varied SES 
clinician and 
family support 
for statins 
Cholesterol 
and risk down, 
not concerned 
anymore 
 
 
Mixed path 
Family support 
statin use and 
behaviour 
change 
 
Hereditary & 
Behaviour 
 
Varied SES, 
family & 
clinician  
support 
for behaviour 
change & 
statins  
Statins brought 
risk down, 
effect of 
behaviour 
change? 
 
 
Behavioural 
path 
Behaviour 
change, focus on 
embodied 
sensations 
 
Hereditary & 
behaviour  
Varied SES,  
some family 
support for 
behaviour 
change  
Feeling better, 
less at risk? 
 
 
Lost 
path 
Overwhelming 
circumstances, 
no preventive 
actions 
 
Hereditary & 
behaviour 
Lower SES, 
poor clinician 
& family 
support, 
difficult life 
circumstances  
Risk perceived 
the same 
 
Table 2. Key features of the four preventive paths identified. 
 
